Zimmer Biomet (NYSE:ZBH) Earns Hold Rating from Needham & Company LLC

Zimmer Biomet (NYSE:ZBH)‘s stock had its “hold” rating restated by equities researchers at Needham & Company LLC in a note issued to investors on Tuesday,Benzinga reports.

A number of other research analysts have also recently commented on the stock. Royal Bank Of Canada cut their price target on shares of Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating on the stock in a report on Thursday, November 6th. BTIG Research reissued a “buy” rating and issued a $112.00 price objective on shares of Zimmer Biomet in a research report on Thursday, January 8th. The Goldman Sachs Group lowered shares of Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 target price on the stock. in a research report on Friday, January 9th. Citigroup lowered their price target on Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating for the company in a report on Thursday, December 11th. Finally, Robert W. Baird restated a “neutral” rating and set a $100.00 price objective (down from $117.00) on shares of Zimmer Biomet in a report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $106.10.

Zimmer Biomet Trading Up 2.8%

Shares of NYSE:ZBH traded up $2.55 during trading hours on Tuesday, hitting $92.28. 1,834,863 shares of the company’s stock traded hands, compared to its average volume of 2,279,722. The firm has a market capitalization of $18.29 billion, a P/E ratio of 22.86, a price-to-earnings-growth ratio of 2.29 and a beta of 0.62. The business has a fifty day moving average price of $90.02 and a 200-day moving average price of $95.68. Zimmer Biomet has a 1 year low of $84.59 and a 1 year high of $114.44. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.04. The firm had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The company’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current year.

Institutional Trading of Zimmer Biomet

Institutional investors and hedge funds have recently bought and sold shares of the business. Key Financial Inc grew its position in shares of Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. raised its stake in Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 116 shares during the period. Cary Street Partners Investment Advisory LLC boosted its holdings in Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 149 shares during the last quarter. Root Financial Partners LLC purchased a new stake in Zimmer Biomet during the third quarter valued at about $31,000. Finally, Flagship Harbor Advisors LLC acquired a new stake in Zimmer Biomet during the fourth quarter worth about $32,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q4 beat on both EPS and revenue: reported $2.42 EPS vs. $2.38 consensus and revenue of $2.24B (sales +10.9% year-over-year), reflecting continued demand for orthopedics. Zimmer Biomet beats quarterly estimates on strong hips, knees device demand
• Neutral Sentiment: Revenue and EPS growth were solid vs. prior year, but investors should dig into product/region breakdowns and conference call commentary for sustainability. Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates
• Neutral Sentiment: Analyst consensus remains muted—street rating recently shown as a “Hold”—so upgrades/downgrades will matter more than the beat itself for further moves. Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Consensus Rating of “Hold” by Analysts
• Negative Sentiment: FY2026 guidance was conservative relative to consensus: EPS guidance of $8.30–8.45 (consensus ~8.44) and revenue guidance roughly $8.4B–$8.6B (consensus ~8.6B), which may cap upside if investors expected a clearer beat. ZBH Q4 Earnings & Revenues Top Estimates, Stock Up in Pre-Market
• Negative Sentiment: Management noted margin contraction in the quarter, which pressures near-term profitability metrics and could weigh on multiple expansion until margin trends reverse. ZBH Q4 Earnings & Revenues Top Estimates, Stock Up in Pre-Market

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.